0001209191-20-065134.txt : 20201223
0001209191-20-065134.hdr.sgml : 20201223
20201223215215
ACCESSION NUMBER: 0001209191-20-065134
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20201221
FILED AS OF DATE: 20201223
DATE AS OF CHANGE: 20201223
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Schenkein David P
CENTRAL INDEX KEY: 0001578200
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38311
FILM NUMBER: 201414329
MAIL ADDRESS:
STREET 1: C/O BLUEBIRD BIO, INC.
STREET 2: 840 MEMORIAL DRIVE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Denali Therapeutics Inc.
CENTRAL INDEX KEY: 0001714899
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 463872213
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 161 OYSTER POINT BLVD.
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: (650) 866-8548
MAIL ADDRESS:
STREET 1: 161 OYSTER POINT BLVD.
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-12-21
0
0001714899
Denali Therapeutics Inc.
DNLI
0001578200
Schenkein David P
C/O DENALI THERAPEUTICS INC.
161 OYSTER POINT BLVD.
SOUTH SAN FRANCISCO
CA
94080
1
0
0
0
Common Stock
2020-12-21
4
S
0
25000
90.0622
D
0
D
Common Stock
2020-12-21
4
S
0
5000
90.0054
D
26232
I
See footnote
Common Stock
31232
I
See footnote
The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan.
The sale price reported in column 4 of Table I represents the weighted average price of the shares sold ranging from $90.00 to $90.38 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
The sale price reported in column 4 of Table I represents the weighted average price of the shares sold ranging from $90.00 to $90.02 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
This number is restated pursuant to an internal review of the Reporting Person's holdings, and reflects the consolidation of shares between trusts associated with the Reporting Person.
The shares are held of record by the David P. Schenkein 2004 Revocable Trust, for which the Reporting Person serves as a trustee.
The shares are held of record by the Amy P. Schenkein 2004 Revocable Trust, for which the Reporting Person's spouse serves as a trustee.
/s/ Tyler Nielsen, by power of attorney
2020-12-23